Maternal Health Pandemic Response Act
Summary
The Maternal Health Pandemic Response Act (S.4550) is an early-stage authorization bill that would allocate up to $130M for CDC maternal health data collection. It has not been passed or funded. Market impact is minimal and indirect.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Authorization of $130M for CDC maternal health data programs — no actual funding yet.
- 2.Early-stage bill (referred to committee) with no hearings scheduled — low passage probability in 119th Congress.
- 3.No direct revenue impact for healthcare companies — tickers included at confidence floor due to distant inference.
Market Implications
No near-term market implications. The bill does not create procurement, subsidies, or regulatory changes that affect corporate earnings. If appropriated and implemented, improved maternal health data could subtly shift R&D priorities at $LLY (diabetes/pregnancy) and (medical devices), but this is a 3-5 year horizon with very low confidence.
Full Analysis
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Authorizes $130M for CDC data collection, surveillance, and research on maternal health outcomes during public health emergencies. No mandated procurement, no regulatory changes for pharmaceutical companies.
Who must act
Centers for Disease Control and Prevention (CDC)
What happens
CDC receives authorization to spend up to $130M on surveillance infrastructure and capacity building for health departments. No direct financial obligation or opportunity for drug manufacturers.
Stock impact
Lilly's maternal health portfolio (e.g., diabetes/pregnancy) is not directly addressed. The bill funds government data systems, not drug development or purchasing. Indirect benefit if future policy relies on this data, but no near-term revenue change.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Tech to Save Moms Act
Moms Matter Act
Medical Device Electronic Labeling Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.